APA (7th ed.) Citation

A, O., S, S., M, S., AM, T., C, D., L, P., . . . G, N. (2021). Aflibercept or bevacizumab in combination with FOLFIRI as second-line treatment of mRAS metastatic colorectal cancer patients: The ARBITRATION study protocol. Therapeutic advances in medical oncology, 13, 1758835921989223. https://doi.org/10.1177/1758835921989223

Chicago Style (17th ed.) Citation

A, Ottaiano, et al. "Aflibercept or Bevacizumab in Combination with FOLFIRI as Second-line Treatment of MRAS Metastatic Colorectal Cancer Patients: The ARBITRATION Study Protocol." Therapeutic Advances in Medical Oncology 13 (2021): 1758835921989223. https://doi.org/10.1177/1758835921989223.

MLA (9th ed.) Citation

A, Ottaiano, et al. "Aflibercept or Bevacizumab in Combination with FOLFIRI as Second-line Treatment of MRAS Metastatic Colorectal Cancer Patients: The ARBITRATION Study Protocol." Therapeutic Advances in Medical Oncology, vol. 13, 2021, p. 1758835921989223, https://doi.org/10.1177/1758835921989223.